Artemisinin Combination Therapy Market Introduction

Artemisinin is a plant derivative isolated from Artemisia annua, or sweet wormwood, which is known to effectively and swiftly reduce the number of plasmodium parasites in the blood of malaria patients. The WHO recommends artemisinin combination therapies (ACTs) as the first line of treatment for uncomplicated plasmodium falciparum malaria and as the second line of treatment for chloroquine-resistant P. vivax malaria.

This therapy combines an artemisinin derivative along with a partner drug, wherein artemisinin aids in reducing the number of parasites and the partner drug eliminates the remaining parasites. Efficacy of the treatment is determined by the drug combined with artemisinin, such as artesunate-mefloquine, dihydroartemisinin–piperaquine, and artemether-lumefantrine.

Falciparum malaria was one of the most common lethal infections which was treated with chloroquine and sulfadoxine-pyrimethamine. However, these drugs are not effective as treatment primarily in the tropical regions owing to the resistance developed against these drugs. According to the Medicines Malaria Venture (MMV), over 445,000 deaths were reported in 2016 due to malaria. The globally rising malaria endemic and the changing climatic conditions would contribute to the trend aiding in the artemisinin combination therapy market growth.

Identify the key factors that will drive your company’s growth, Request a brochure of this report here

Artemisinin Combination Therapy Market- Competitive Landscape

The strategies adopted by the market players to enhance their market position include indication extension, focus on geographic expansion, and research & development. The national funding allocations, as announced by the Global Fund for 2018-2020, report that the funding available for the promotion of malaria programs is around US$1 billion.

Novartis AG

Novartis AG, established in 1895, is engaged in research, development, manufacturing and marketing of healthcare products across a range of areas, including neuroscience, ophthalmology, immunology, hepatology, respiratory, cardiology, dermatology, and cardio metabolic.


Sanofi, a leading pharmaceutical company is engaged in the manufacturing of prescription pharmaceuticals and vaccines. It is engaged in the development of cardiovascular, metabolic disorder, central nervous system (CNS), oncology, and thrombosis drugs and medicines.

Ipca Laboratories Ltd.

Ipca Laboratories is an Indian pharmaceutical company engaged in the manufacturing of over 350 formulations and 80 APIs for a range of therapeutic indications. According to the company, it is the market leader in India for anti-malarials with a market share of over 34% in 2018.

Artemisinin Combination Therapy Market - Dynamics

Growing malaria endemic

Malaria is a major health concern in endemic countries such as Sudan, wherein over 75% of the population is at the risk of acquiring the disease. Moreover, the widespread presence of chloroquine-resistant strains of P. falciparum in the malaria endemic countries makes artemisinin combination therapy the preferred choice of treatment. This is projected to fuel the growth of the artemisinin combination therapy market.

Expanding operations in future? To get the perfect launch ask for a custom report here

Increase in the procurement of ACT treatment courses

Increase in access to ACTs in the malaria-endemic countries contributes to the rising success in reducing the global malaria burden. According to the WHO, over 2.7 billion ACT treatment courses were procured by global countries between 2010 and 2017. Moreover, over 62% of these procurements were made by the public sector. Strong pipeline for the development of new anti-malarial drugs and launch of newer artemisinin combinations for the treatment of malaria boost to the growth of the global artemisinin combination therapy market.

Challenges related to the availability of raw materials

Challenges pertaining to the availability of intermediate products and raw materials in the production of artemisinin-based combination therapies from agricultural sources are expected to restrain the global artemisinin combination therapy market. Furthermore, volatility in the artemisinin market leading to concerns over supply tightening could create significant risks to patients and market participants.

Artemisinin Combination Therapy Market Segmentation

Global artemisinin combination therapy market can be segmented on the basis of

  • Type
  • Distribution Channel

Based on the type, the artemisinin combination therapy market is segmented into

  • Artesunate-sulfadoxine-pyrimethamine
  • Artesunate-amodiaquine
  • Artesunate-pyronaridine
  • Artemether-lumefantrine
  • Artesunate-mefloquine
  • Artesunate-atovaquone-proguanil
  • Artesunate-chlorproguanil-dapsone
  • Dihydroartemisinin-piperaquine

The artemether-lumefantrine segment dominated the artemisinin combination therapy market in 2018, as it was the first ACT to be approved for the treatment of malaria by the WHO for its efficacy, safety, and quality.

Based on the distribution channel, the artemisinin combination therapy market is segmented into

  • Public sector providers
  • Retail providers
  • Others

In the African countries, where retail providers play a major role in the drug distribution, drug shops accounted for a major share. The others segment includes pharmacies, grocery stores, and itinerant hawkers.

The report on artemisinin combination therapy market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The artemisinin combination therapy market report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The artemisinin combination therapy market report also maps the qualitative impact of various market factors on market segments and geographies.    

Regional analysis for Artemisinin Combination Therapy market includes:

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East & Africa (MEA)

Middle East & Africa accounted for major share of the global artemisinin combination therapy market in 2018, owing to malaria endemic in the region. Additionally, the initiatives taken by the government and non-government organizations to spread awareness about ACT treatment for malaria contribute to the growth of the market in the region. Moreover, rise in demand for ACT in malaria endemic countries in Africa such as Uganda and Nigeria boosts the growth of the market in the region.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Artemisinin Combination Therapy Market

Pre Book